Boost 2028 Accelerating "Strong Sumitomo Pharma"
March 2, 2026
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
Table of Contents
Part I Review of Reboot 2027
Part II Boost 2028
Sumitomo Pharma's Growth Acceleration
Accelerating Growth Trend
Demonstrating the True Value of R&D
Developing and Establishing Future Growth Engines
PL Management and Financial KPIs
Governance Transformation
© Sumitomo Pharma Co., Ltd. All Rights Reserved. 2
Review of Reboot 2027
Achieved our financial targets ahead of schedule
Expanding sales of 3 key products beyond expectations Delivering record-high profits in the outlook for FY2025
Driving value creation
as an R&D-driven pharmaceutical company
Toward the world's first commercialization of iPS cell-derived products, achieved NDA submission of iPSC-PD (raguneprocel*) in Japan and started the investigator-initiated study in North America
Accelerating in-house clinical development to enable the fastest possible launch of the two oncology compounds
Observing favorable data in safety, tolerability, immunogenicity and cross-reactivity from the interim analysis of a Ph1 study in Europe
* The product name is "AMCHEPRY®". Conditional and time-limited approval was endorsed at the Subcommittee on Regenerative Medicine Products and Biological Technology, Pharmaceutical Affairs Council, Ministry of Health, Labour and Welfare held on February 19, 2026 (prior to official approval by the Minister of Health, Labour and Welfare).
© Sumitomo Pharma Co., Ltd. All Rights Reserved. 3
Achieved Financial Targets Ahead of Schedule
Delivering record-high core operating profits in FY2025 and expecting to achieve the Reboot 2027 financial targets ahead of schedule
Maintaining disciplined SG&A and R&D expenses management to accelerate regrowth following the V-shaped recovery
555.5
Revenue Core operating profit (Billions of JPY)
449.0
398.8
314.6
107.0
43.2
Sales of 3 key products Core operating profit
（Excluding one-time factors*）
Free cash flow
（Excluding divestment-related income）
Interest-bearing debt (End of fiscal year)
Financial Targets under "Reboot" in FY2027
250 billion yen
Consistently more than
25 billion yen Maintain profitability
Reduce to less than
200 billion yen
As early as possible
FY2025
Forecasts
Approx. 260 billion yen Approx. 43 billion yen Approx. 47 billion yen
Approx. 220 billion yen
(Net Debt Approx. 190 billion yen)
16.4
* Includes sales milestone income and profit from the divestment of the Asian business
Cost Management Performance (FY2025 forecast vs FY2022)
(133.0)
FY2022 FY2023 FY2024 FY2025
Forecasts
SG&A Expense
FY2022
305.6 B yen
FY2025
Approx. 156 B yen
R&D Expense
FY2022
106.1 B yen
FY2025
Approx. 43 B yen
Number of Employees （Consolidated）
End of FY2022
6,250
End of Sep. 2025
3,098
© Sumitomo Pharma Co., Ltd. All Rights Reserved. 4
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |